Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer Publisher Pubmed



Jalalvand M^{1, 2} ; Darbeheshti F^{3, 4} ; Rezaei N^{5, 6, 7}
Source: Immunotherapy Published:2021

Abstract

Cancer initiation and progression are associated with immune system responses. Tumor cells use various tricks to scape of immune system, such as activating immune checkpoint pathways that induce immunosuppressive functions. Among the different immune checkpoint receptors, CTLA-4 and PD-1/PD-L1 are prominent therapeutic targets in different cancers. Although the US FDA has approved some immune checkpoint inhibitors for several cancers, concerning breast cancer still different clinical trials are looking for optimizing efficacy and decreasing immune-related adverse events. This review will discuss the existing body of knowledge with regard to cross-talk between immune system and tumor cells and then explore immune checkpoint-related signaling pathways in the context of breast tumors. Finally, we highlight the application of different immune checkpoint blockers in breast cancer patients. © 2021 Immunotherapy. All rights reserved.